PSORIASIS ON THE SCALP
Drag the slider to switch between images.
These photos of a real patient were taken in a clinical trial outside of the trials discussed in this website.
Individual results may vary.
PSORIASIS ON THE LEG
Drag the slider to switch between images.
These are healthcare professional-submitted* photos of a real patient that were taken in the office, outside of clinical trials.
* | Healthcare professionals were compensated for the use of their photos. Individual results may vary. |
PSORIASIS ON THE ARM
Drag the slider to switch between images.
These are healthcare professional-submitted* photos of a real patient that were taken in the office, outside of clinical trials.
* | Healthcare professionals were compensated for the use of their photos. Individual results may vary. |
PSORIASIS ON THE BACK
Drag the slider to switch between images.
These are healthcare professional-submitted* photos of a real patient that were taken in the office, outside of clinical trials.
* | Healthcare professionals were compensated for the use of their photos. Individual results may vary. |
CLEARER SKIN AT 16 WEEKS
As seen in clinical trials not affiliated with the photos above.
In one study, a majority of people taking SOTYKTU saw 75% CLEARER SKIN at Week 16 vs those taking placebo (53% vs 9%).
Skin clearance was also measured in a different way in that study, where half of people taking SOTYKTU saw CLEAR OR ALMOST CLEAR SKIN at Week 16 vs 9% taking placebo.
In the same study, 16% of people saw COMPLETELY CLEAR SKIN at Week 16 compared to 1% taking placebo.
Among people with plaques on their scalp, 60% saw a clear or almost clear scalp with SOTYKTU compared to 17% with placebo at Week 16.
Your results may vary.
SOTYKTU was studied in two large clinical trials:
- 1684 adults were studied
- 841 received SOTYKTU, 422 received Otezla® (apremilast), and 421 received placebo (a pill with no medicine)
- Patients were assessed at 16, 24, and 52 weeks